

REFERENCES

1. Abraham EP, Chain E. An enzyme from bacteria able to destroy penicillin. *Nature*. 1940;146:837
2. Ambler RP. The structure of β -lactamases. *Phil Trans R Soc Lond Biol*. 1980;289:321–331.
3. Ambler RP, Coulson AF, Frère JM, Ghuysen JM, Joris B, Forsman M, Levesque RC *et al*. A standard numbering scheme for the class A β -lactamases. *Biochem J*. 1991;276 (Pt 1):269-70.
4. Barthélémy M, Péduzzi J, Ben Yaghlane H, Labia R. Single amino acid substitution between SHV-1 β -lactamase and cefotaxime-hydrolyzing SHV-2 enzyme. *FEBS Lett*. 1988;231(1):217-20.
5. Barthélémy M, Péduzzi J, Bernard H, Tancredi C, Labia R. Close amino acid sequence relationship between the new plasmid-mediated extended-spectrum β -lactamase MEN-1 and chromosomally encoded enzymes of *Klebsiella oxytoca*. *Biochim Biophys Acta*. 1992;1122(1):15-22.
6. Bauernfeind A, Grimm H, Schweighart S. A new plasmidic cefotaximase in a clinical isolate of *Escherichia coli*. *Infection*. 1990;18(5):294-8.
7. Bauernfeind A, Stemplinger I, Jungwirth R, Ernst S, Casellas JM. Sequences of β -lactamase genes encoding CTX-M-1 (MEN-1) and CTX-M-2 and relationship of their amino acid sequences with those of other β -lactamases. *Antimicrob Agents Chemother*. 1996;40(2):509-13
8. Beesley T, Gascoyne N, Knott-Hunziker V, Petursson S, Waley SG, Jaurin B, *et al*. The inhibition of class C β -lactamases by boronic acids. *Biochem J*. 1983;209(1):229-33.

9. Bentley R, Meganathan R. Biosynthesis of vitamin K (menaquinone) in bacteria. *Microbiol Rev.* 1982; 46(3):241–280.
10. Bernard H, Tancrede C, Livrelli V, Morand A, Barthelemy M, Labia R. A novel plasmid-mediated extended-spectrum β -lactamase not derived from TEM- or SHV-type enzymes. *J Antimicrob Chemother.* 1992;29(5):590-2.
11. Bin C, Hui W, Renyuan Z, Yongzhong N, Xiuli X, Yingchun X, *et al.* Outcome of cephalosporin treatment of bacteremia due to CTX-M-type extended-spectrum β -lactamase-producing *Escherichia coli*. *Diagn Microbiol Infect Dis.* 2006;56(4):351-7
12. Blazquez J, Morosini MI, Negri MC, Baquero F. Selection of naturally occurring extended-spectrum TEM β -lactamase variants by fluctuating β -lactam pressure. *Antimicrob Agents Chemother.* 2000;44(8):2182-2184.
13. Bonnet R, De Champs C, Sirot D, Chanal C, Labia R, Sirot J. Diversity of TEM mutants in *Proteus mirabilis*. *Antimicrob Agents Chemother.* 1999;43(11):2671-7.
14. Bonnet R. Growing group of extended-spectrum β -lactamases: the CTX-M enzymes. *Antimicrob Agents Chemother.* 2004;48(1):1-14.
15. Boyd DA¹, Tyler S, Christianson S, McGeer A, Muller MP, Willey BM. Complete nucleotide sequence of a 92-kilobase plasmid harboring the CTX-M-15 extended-spectrum β -lactamase involved in an outbreak in long-term-care facilities in Toronto, Canada. *Antimicrob Agents Chemother.* 2004;48(10):3758-64.
16. Bradford PA, Urban C, Jaiswal A, Mariano N, Rasmussen BA, Projan SJ, *et al.* SHV-7, a novel cefotaxime-hydrolyzing β -lactamase, identified in *Escherichia coli* isolates from hospitalized nursing home patients. *Antimicrob Agents Chemother.* 1995;39(4):899-905.

17. Bradford PA, Urban C, Mariano N, Projan SJ, Rahal JJ, Bush K. Imipenem resistance in *Klebsiella pneumoniae* is associated with the combination of ACT-1, a plasmid-mediated AmpC β -lactamase, and the loss of an outer membrane protein. *Antimicrob Agents Chemother.* 1997;41(3):563-9.
18. Bradford PA. Extended-spectrum β -lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. *Clin Microbiol Rev.* 2001;14(4):933-51
19. Bush K, Macalintal C, Rasmussen BA, Lee VJ, Yang Y. Kinetic interactions of tazobactam with β -lactamases from all major structural classes. *Antimicrob Agents Chemother.* 1993;37(4):851-8.
20. Bush K, Jacoby GA, Medeiros AA. A functional classification scheme for β -lactamases and its correlation with molecular structure. *Antimicrob Agents Chemother.* 1995;39(6):1211-1233.
21. Bush K. Extended-spectrum β -lactamases in North America, 1987-2006. *Clin Microbiol Infect.* 2008 Jan;14 Suppl 1:134-43.
22. Cantón R, Coque TM. The CTX-M β -lactamase pandemic. *Curr Opin Microbiol.* 2006;9(5):466-75.
23. Carattoli A. Resistance plasmid families in Enterobacteriaceae. *Antimicrob Agents Chemother.* 2009;53(6):2227-38.
24. Chanawong A, M'Zali FH, Heritage J, Lulitanond A, Hawkey PM. SHV-12, SHV-5, SHV-2a and VEB-1 extended-spectrum β -lactamases in Gram-negative bacteria isolated in a university hospital in Thailand. *J Antimicrob Chemother.* 2001;48(6):839-52.
25. Chanawong A, Lulitanond A, Kaewkes W, Lulitanond V, Srigulbutr S, Homchampa P. CTX-M extended-spectrum β -lactamases among clinical isolates of Enterobacteriaceae in a Thai university hospital. *Southeast Asian J Trop Med Public Health.* 2007;38(3):493-500.

26. Chen CC, Smith TJ, Kapadia G, Wäsch S, Zawadzke LE, Coulson A, *et al.* Structure and kinetics of the β -lactamase mutants S70A and K73H from *Staphylococcus aureus* PC1. *Biochemistry*. 1996;35(38):12251-8.
27. Christensen H, Martin MT, Waley SG. β -lactamases as fully efficient enzymes. Determination of all the rate constants in the acyl-enzyme mechanism. *Biochem J*. 1990;266(3):853-61.
28. CLSI. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard—Ninth Edition. CLSI document M07-A9. Wayne, PA: Clinical and Laboratory Standards Institute; 2012.
29. Connell I, Agace W, Klemm P, Schembri M, Mårild S, Svanborg C. Type 1 fimbrial expression enhances *Escherichia coli* virulence for the urinary tract. *Proc Natl Acad Sci U S A*. 1996 3;93(18):9827–9832.
30. Dalenne C, Da Costa A, Decré D, Favier C, Arlet G. Development of a set of multiplex PCR assays for the detection of genes encoding important beta-lactamases in Enterobacteriaceae. *J Antimicrob Chemother*. 2010 Mar;65(3):490-5.
31. Darnton NC, Turner L, Rojevsky S and Berg HC. On torque and tumbling in swimming *Escherichia coli*. *J Bacteriol*. 2007;189(5):1756-1764.
32. Datta N, Kontomichalou P. Penicillinase synthesis controlled by infectious R factors in Enterobacteriaceae. *Nature*. 1965;208(5007):239-241.
33. Djamdjian L, Naas T, Tandé D, Cuzon G, Hanrotel-Saliou C, Nordmann P. CTX-M-93, a CTX-M variant lacking penicillin hydrolytic activity. *Antimicrob Agents Chemother*. 2011;55(5):1861-6.
34. Domingues S, da Silva GJ, Nielsen KM. Integrons: Vehicles and pathways for horizontal dissemination in bacteria. *Mob Genet Elements*. 2012;2(5):211-223.

35. Drawz SM, Bonomo RA. Three decades of β -lactamase inhibitors. *Clin Microbiol Rev.* 2010;23(1):160-201.
36. Du Bois SK, Marriott MS, Amyes SG. TEM- and SHV-derived extended-spectrum β -lactamases: relationship between selection, structure and function. *J Antimicrob Chemother.* 1995;35(1):7-22.
37. Dubus A, Normark S, Kania M, Page MG. The role of tyrosine 150 in catalysis of β -lactam hydrolysis by AmpC β -lactamase from *Escherichia coli* investigated by site-directed mutagenesis. *Biochemistry.* 1994;33(28):8577-86.
38. Edén CS, Hansson HA. *Escherichia coli* pili as possible mediators of attachment to human urinary tract epithelial cells. *Infect Immun.* 1978;21(1):229-237.
39. El Harrif-Heraud Z, Arpin C, Benliman S, Quentin C. Molecular epidemiology of a nosocomial outbreak due to SHV-4-producing strains of *Citrobacter diversus*. *J Clin Microbiol.* 1997;35(10):2561-2567.
40. Eriksson-Greenberg KG, Boman HG, Jansson JA, Thorén S. Resistance of *Escherichia coli* to Penicillins I. Genetic Study of Some Ampicillin-Resistant Mutants. *J Bacteriol.* 1965;90(1):54-62.
41. Eriksson-Greenberg KG. Resistance of *Escherichia coli* to penicillins. II. An improved mapping of the ampA gene. *Genet Res.* 1968;12(2):147-56.
42. Fisher JF, Meroueh SO, Mobashery S. Bacterial resistance to β -lactam antibiotics: compelling opportunism, compelling opportunity. *Chem Rev.* 2005;105(2):395-424.
43. Flemming A. On the Antibacterial Action of Cultures of a *Penicillium*, with Special Reference to their Use in the Isolation of *B. influenzae*. *Br J Exp Pathol.* 1929;10(3):226-236.
44. Fotadar U, Zaveloff P, Terracio L. Growth of *Escherichia coli* at elevated temperatures. *J Basic Microbiol.* 2005; 45 (5):403-404.

45. Gazouli M, Tzouvelekis LS, Prinarakis E, Miriagou V, Tzelepi E. Transferable cefoxitin resistance in enterobacteria from Greek hospitals and characterization of a plasmid-mediated group 1 β -lactamase (LAT-2). *Antimicrob Agents Chemother.* 1996;40(7):1736-40.
46. Gazouli M, Tzouvelekis LS, Vatopoulos AC, Tzelepi E. Transferable class C β -lactamases in *Escherichia coli* strains isolated in Greek hospitals and characterization of two enzyme variants (LAT-3 and LAT-4) closely related to *Citrobacter freundii* AmpC β -lactamase. *J Antimicrob Chemother.* 1998;42(4):419-25.
47. Gillings M, Boucher Y, Labbate M, Holmes A, Krishnan S, Holley M, *et al.* The evolution of class 1 integrons and the rise of antibiotic resistance. *J Bacteriol.* 2008;190(14):5095-100.
48. Gniadkowski M, Schneider I, Pałucha A, Jungwirth R, Mikiewicz B, Bauernfeind A. Cefotaxime-resistant Enterobacteriaceae isolates from a hospital in Warsaw, Poland: identification of a new CTX-M-3 cefotaxime-hydrolyzing β -lactamase that is closely related to the CTX-M-1/MEN-1 enzyme. *Antimicrob Agents Chemother.* 1998;42(4):827-832.
49. Gonzalez Leiza M, Perez-Diaz JC, Ayala J, Casellas JM, Martinez-Beltran J, Bush K, *et al.* Gene sequence and biochemical characterization of FOX-1 from *Klebsiella pneumoniae*, a new AmpC-type plasmid-mediated β -lactamase with two molecular variants. *Antimicrob Agents Chemother.* 1994;38(9):2150-7.
50. Gunther NW 4th, Lockett V, Johnson DE, Mobley HL. In vivo dynamics of type 1 fimbria regulation in uropathogenic *Escherichia coli* during experimental urinary tract infection. *Infect Immun.* 2001;69(5):2838-2846.
51. Hammond DS, Harris T, Bell J, Turnidge J, Giffard PM. Selection of SHV extended-spectrum- β -lactamase-dependent cefotaxime and ceftazidime resistance in *Klebsiella pneumoniae* requires a plasmid-borne *bla*_{SHV} gene. *Antimicrob Agents Chemother.* 2008;52(2):441-5.

52. Hedges RW, Jacob AE. Transposition of ampicillin resistance from RP4 to other replicons. *Mol Gen Genet.* 1974;132(1):31-40.
53. Heffron F, Sublett R, Hedges RW, Jacob A, Falkow S. Origin of the TEM- β -lactamase gene found on plasmids. *J Bacteriol.* 1975;122(1):250-6.
54. Heritage J, Hawkey PM, Todd N, Lewis IJ. Transposition of the gene encoding a TEM-12 extended-spectrum β -lactamase. *Antimicrob Agents Chemother.* 1992;36(9):1981-6.
55. Huletsky A, Knox JR, Levesque RC. Role of Ser-238 and Lys-240 in the hydrolysis of third-generation cephalosporins by SHV-type β -lactamases probed by site-directed mutagenesis and three-dimensional modeling. *J Biol Chem.* 1993;268(5):3690-7.
56. Horii T, Arakawa Y, Ohta M, Sugiyama T, Wacharotayankun R, Ito H, *et al.* Characterization of a plasmid-borne and constitutively expressed *bla*_{MOX-1} gene encoding AmpC-type β -lactamase. *Gene.* 1994;139(1):93-8.
57. Hsu SC, Chiu TH, Pang JC, Hsuan-Yuan CH, Chang GN, Tsen HY. Characterisation of antimicrobial resistance patterns and class 1 integrons among *Escherichia coli* and *Salmonella enterica* serovar *Choleraesuis* strains isolated from humans and swine in Taiwan. *Int J Antimicrob Agents.* 2006;27(5):383-91.
58. Issack MI, Shannon KP, Qureshi SA, French GL. Extended-spectrum β -lactamase in *Salmonella* spp. *J Hosp Infect.* 1995;30(4):319-21.
59. Jacobs C, Frère JM, Normark S. Cytosolic intermediates for cell wall biosynthesis and degradation control inducible β -lactam resistance in gram-negative bacteria. *Cell.* 1997;88(6):823-32.
60. Jacoby GA, Medeiros AA. More extended-spectrum β -lactamases. *Antimicrob Agents Chemother.* 1991;35(9):1697-1704.

61. Jacoby GA, Munoz-Price LS. The new β -lactamases. *N Engl J Med.* 2005;352(4):380-91.
62. Jacoby GA. AmpC β -lactamases. *Clin Microbiol Rev.* 2009;22(1):161-82
63. Jaurin B, Grundström T. ampC cephalosporinase of *Escherichia coli* K-12 has a different evolutionary origin from that of β -lactamases of the penicillinase type. *Proc Natl Acad Sci U S A.* 1981;78(8):4897-901.
64. Kang MS, Besser TE, Call DR. Variability in the region downstream of the blaCMY-2 β -lactamase gene in *Escherichia coli* and *Salmonella enterica* plasmids. *Antimicrob Agents Chemother.* 2006;50(4):1590-3.
65. Kaper JB, Nataro JP, Mobley HL. Pathogenic *Escherichia coli*. *Nat Rev Microbiol.* 2004;2(2):123-140.
66. Kazmierczak A, Cordin X, Duez JM, Siebor E, Pechinot A, Sirot J. Differences between clavulanic acid and sulbactam in induction and inhibition of cephalosporinases in enterobacteria. *J Int Med Res.* 1990;18 (Suppl 4):67D-77D.
67. Kimura S, Ishiguro M, Ishii Y, Alba J, Yamaguchi K. Role of a mutation at position 167 of CTX-M-19 in ceftazidime hydrolysis. *Antimicrob Agents Chemother.* 2004;48(5):1454-60.
68. Kiratisin P, Apisarnthanarak A, Laesripa C, Saifon P. Molecular characterization and epidemiology of extended-spectrum- β -lactamase-producing *Escherichia coli* and *Klebsiella pneumoniae* isolates causing health care-associated infection in Thailand, where the CTX-M family is endemic. *Antimicrob Agents Chemother.* 2008;52(8):2818-24.
69. Kiratisin P, Apisarnthanarak A, Saifon P, Laesripa C, Kitphati R, Mundy LM. The emergence of a novel ceftazidime-resistant CTX-M extended-spectrum β -lactamase, CTX-M-55, in both community-onset and hospital-acquired infections in Thailand. *Diagn Microbiol Infect Dis.* 2007;58(3):349-55.

70. Knothe H, Shah P, Krcmery V, Antal M, Mitsuhashi S. Transferable resistance to cefotaxime, ceftazidime, cefamandole and cefuroxime in clinical isolates of *Klebsiella pneumoniae* and *Serratia marcescens*. *Infection*. 1983;11(6):315-7.
71. Knott-Hunziker V, Petursson S, Jayatilake GS, Waley SG, Jaurin B, Grundström T. Active sites of β -lactamases. The chromosomal β -lactamases of *Pseudomonas aeruginosa* and *Escherichia coli*. *Biochem J*. 1982;201(3):621-7.
72. Kopecko DJ, Cohen SN. Site specific recA--independent recombination between bacterial plasmids: involvement of palindromes at the recombinational loci. *Proc Natl Acad Sci U S A*. 1975;72(4):1373-7.
73. Korhonen TK, Valtonen MV, Parkkinen J, Väisänen-Rhen V, Finne J, Orskov F, et al. Serotypes, hemolysin production, and receptor recognition of *Escherichia coli* strains associated with neonatal sepsis and meningitis. *Infect Immun*. 1985; 48(2): 486-491.
74. Korhonen TK, Virkola R, Holthöfer H. Localization of binding sites for purified *Escherichia coli* P fimbriae in the human kidney. *Infect Immun*. 1986;54(2):328-32.
75. Lartigue MF, Poirel L, Aubert D, Nordmann P. In vitro analysis of ISEcp1B-mediated mobilization of naturally occurring β -lactamase gene blaCTX-M of *Kluyvera ascorbata*. *Antimicrob Agents Chemother*. 2006;50(4):1282-6.
76. Linström EB, Boman HG, Steele BB. Resistance of *Escherichia coli* to penicillins. VI. Purification and characterization of the chromosomally mediated penicillinase present in ampA-containing strains. *J Bacteriol*. 1970;101(1):218-31.
77. Livermore DM. β -Lactamases in laboratory and clinical resistance. *Clin Microbiol Rev*. 1995;8(4):557-84.
78. Livermore DM, Canton R, Gniadkowski M, Nordmann P, Rossolini GM, Arlet G, et al. CTX-M: changing the face of ESBLs in Europe. *J Antimicrob Chemother*. 2007;59(2):165-74.

79. Livermore DM. Defining an extended-spectrum β -lactamase. *Clin Microbiol Infect.* 2008;14(Suppl 1):3-10.
80. Lulitanond A, Kaewkes W. Prevalence of extended-spectrum β -lactamase (ESBL) production in Gram-negative bacilli isolated from Srinagarind Hospital Thailand. *J Infect Dis Antimicrob Agents.* 1999;16:155-9.
81. Ma L, Ishii Y, Ishiguro M, Matsuzawa H, Yamaguchi K. Cloning and sequencing of the gene encoding Toho-2, a class A β -lactamase preferentially inhibited by tazobactam. *Antimicrob Agents Chemother.* 1998;42(5):1181-6.
82. Mabilat C, Lourençao-Vital J, Goussard S, Courvalin P. A new example of physical linkage between Tn1 and Tn21: the antibiotic multiple-resistance region of plasmid pCFF04 encoding extended-spectrum β -lactamase TEM-3. *Mol Gen Genet.* 1992;235(1):113-121.
83. Maina D, Revathi G, Kariuki S, Ozwara H. Genotypes and cephalosporin susceptibility in extended-spectrum β -lactamase producing Enterobacteriaceae in the community. *J Infect Dev Ctries.* 2012;6(6):470-7.
84. Manoharan A, Sugumar M, Kumar A, Jose H, Mathai D, Khilnani GC, *et al.* Phenotypic & molecular characterization of AmpC β -lactamases among *Escherichia coli*, *Klebsiella* spp. & *Enterobacter* spp. from five Indian Medical Centers. *Indian J Med Res.* 2012;135:359-64.
85. Marcadé G, Deschamps C, Boyd A, Gautier V, Picard B, Branger C. Replicon typing of plasmids in *Escherichia coli* producing extended-spectrum β -lactamases. *J Antimicrob Chemother.* 2009;63(1):67-71.
86. Martinez-Freijo P, Fluit AC, Schmitz FJ, Grek VS, Verhoef J, Jones ME. Class I integrons in Gram-negative isolates from different European hospitals and association with decreased susceptibility to multiple antibiotic compounds. *J Antimicrob Chemother.* 1998;42(6):689-96.

87. Matsumoto Y, Ikeda F, Kamimura T, Yokota Y, Mine Y. Novel plasmid-mediated β -lactamase from *Escherichia coli* that inactivates oxyimino-cephalosporins. *Antimicrob Agents Chemother.* 1988;32(8):1243-6.
88. Medeiros AA. β -lactamases. *Br Med Bull.* 1984;40(1):18-27.
89. Medeiros AK, Mayer H, Opal HM. Plasmid-mediated β -lactamases. *Antimicrob. Newsl.* 1988;5:61–65.
90. Migula W. Bacteriaceae (Stabchenbacterien) In: Engler A and Prantl K (ed.) Die Natürlichen Pflanzenfamilien. 1895; 20–30.
91. Monnaie D, Frere JM. Interaction of clavulanate with class C β -lactamases. *FEBS Lett.* 1993;334(3):269-71.
92. M'Zali FH, Heritage J, Gascoyne-Binzi DM, Denton M, Todd NJ, Hawkey PM. Transcontinental importation into the UK of *Escherichia coli* expressing a plasmid-mediated AmpC-type β -lactamase exposed during an outbreak of SHV-5 extended-spectrum β -lactamase in a Leeds hospital. *J Antimicrob Chemother.* 1997;40(6):823-31.
93. Naas T, Philippon L, Poirel L, Ronco E, Nordmann P. An SHV-derived extended-spectrum β -lactamase in *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother.* 1999;43(5):1281-1284.
94. Oefner C, D'Arcy A, Daly JJ, Gubernator K, Charnas RL, Heinze I, *et al.* Refined crystal structure of β -lactamase from *Citrobacter freundii* indicates a mechanism for β -lactam hydrolysis. *Nature.* 1990;343(6255):284-8.
95. Oliver A, Coque TM, Alonso D, Valverde A, Baquero F, Cantón R. CTX-M-10 linked to a phage-related element is widely disseminated among Enterobacteriaceae in a Spanish hospital. *Antimicrob Agents Chemother.* 2005;49(4):1567-71.
96. Orskov I, Orskov F, Jann B, Jann K. Serology, chemistry, and genetics of O and K antigens of *Escherichia coli*. *Bacteriol Rev.* 1977;41(3):667-710.

97. Oteo J¹, Navarro C, Cercenado E, Delgado-Iribarren A, Wilhelmi I, Orden B et al. Spread of *Escherichia coli* strains with high-level cefotaxime and ceftazidime resistance between the community, long-term care facilities, and hospital institutions. *J Clin Microbiol.* 2006;44(7):2359-66.
98. Pai H, Kang CI, Byeon JH, Lee KD, Park WB, Kim HB, et al. Epidemiology and clinical features of bloodstream infections caused by AmpC-type- β -lactamase-producing *Klebsiella pneumoniae*. *Antimicrob Agents Chemother.* 2004;48(10):3720-8.
99. Papanicolaou GA, Medeiros AA, Jacoby GA. Novel plasmid-mediated β -lactamase (MIR-1) conferring resistance to oxyimino- and alpha-methoxy β -lactams in clinical isolates of *Klebsiella pneumoniae*. *Antimicrob Agents Chemother.* 1990;34(11):2200-9.
100. Park YS, Yoo S, Seo MR, Kim JY, Cho YK, Pai H. Risk factors and clinical features of infections caused by plasmid-mediated AmpC β -lactamase-producing Enterobacteriaceae. *Int J Antimicrob Agents.* 2009;34(1):38-43.
101. Partridge SR. Analysis of antibiotic resistance regions in Gram-negative bacteria. *FEMS Microbiol Rev.* 2011 Sep;35(5):820-855.
102. Paterson DL. Recommendation for treatment of severe infections caused by Enterobacteriaceae producing extended-spectrum β -lactamases (ESBLs). *Clin Microbiol Infect.* 2000;6(9):460-3.
103. Paterson DL, Ko WC, Von Gottberg A, Casellas JM, Mulazimoglu L, Klugman KP, et al. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum β -lactamases: implications for the clinical microbiology laboratory. *J Clin Microbiol.* 2001;39(6):2206-12.
104. Paterson DL, Bonomo RA. Extended-spectrum β -lactamases: a clinical update. *Clin Microbiol Rev.* 2005;18(4):657-86.

105. Perez F, Endimiani A, Hujer KM, Bonomo RA. The continuing challenge of ESBLs. *Curr Opin Pharmacol*. 2007;7(5):459-69.
106. Peter-Getzlaff S, Polsfuss S, Poledica M, Hombach M, Giger J, Böttger EC. Detection of AmpC β -lactamase in *Escherichia coli*: comparison of three phenotypic confirmation assays and genetic analysis. *J Clin Microbiol*. 2011;49(8):2924-32.
107. Philippon A, Arlet G, Jacoby GA. Plasmid-determined AmpC-type β -lactamases. *Antimicrob Agents Chemother*. 2002;46(1):1-11.
108. Phongpaichi S, Wuttananupan K, Samasanti W. Class 1 integrons and multidrug resistance among *Escherichia coli* isolates from human stools. *Southeast Asian J Trop Med Public Health*. 2008;39(2):279-87.
109. Pitton JS. Mechanisms of bacterial resistance to antibiotics. *Ergeb Physiol*. 1972;65:15-93.
110. Prinarakis EE, Miriagou V, Tzelepi E, Gazouli M, Tzouveleki LS. Emergence of an inhibitor-resistant β -lactamase (SHV-10) derived from an SHV-5 variant. *Antimicrob Agents Chemother*. 1997;41(4):838-40.
111. Podbielski A, Schönling J, Melzer B, Haase G. Different promoters of SHV-2 and SHV-2a β -lactamase lead to diverse levels of cefotaxime resistance in their bacterial producers. *J Gen Microbiol*. 1991;137(7):1667-75.
112. Poirel L, Naas T, Le Thomas I, Karim A, Bingen E, Nordmann P. CTX-M-type extended-spectrum β -lactamase that hydrolyzes ceftazidime through a single amino acid substitution in the omega loop. *Antimicrob Agents Chemother*. 2001;45(12):3355-61.
113. Poirel L, Kämpfer P, Nordmann P. Chromosome-encoded Ambler class A β -lactamase of *Kluyvera georgiana*, a probable progenitor of a subgroup of CTX-M extended-spectrum β -lactamases. *Antimicrob Agents Chemother*. 2002;46(12):4038-40.

114. Poirel L, Decousser JW, Nordmann P. Insertion sequence ISEcp1B is involved in expression and mobilization of a bla(CTX-M) β -lactamase gene. *Antimicrob Agents Chemother.* 2003;47(9):2938-45.
115. Poirel L, Bonnin RA, Nordmann P. Genetic support and diversity of acquired extended-spectrum β -lactamases in Gram-negative rods. *Infect Genet Evol.* 2012;12(5):883-93.
116. Prasad K, Kumar A, Gupta PK, Singhal T. Third generation cephalosporins versus conventional antibiotics for treating acute bacterial meningitis. *Cochrane Database Syst Rev.* 2007;17(4):CD001832.
117. Ramphal R, Ambrose PG. Extended-spectrum β -lactamases and clinical outcomes: current data. *Clin Infect Dis.* 2006 Apr 15;42 Suppl 4:S164-72.
118. Rasheed JK, Jay C, Metchock B, Berkowitz F, Weigel L, Crellin J, *et al.* Evolution of extended-spectrum β -lactam resistance (SHV-8) in a strain of *Escherichia coli* during multiple episodes of bacteremia. *Antimicrob Agents Chemother.* 1997;41(3):647-53.
119. Rasmussen BA, Bradford PA, Quinn JP, Wiener J, Weinstein RA, Bush K. Genetically diverse ceftazidime-resistant isolates from a single center: biochemical and genetic characterization of TEM-10 β -lactamases encoded by different nucleotide sequences. *Antimicrob Agents Chemother.* 1993;37(9):1989-1992.
120. Reis RS, Horn F. Enteropathogenic *Escherichia coli*, *Salmonella*, *Shigella* and *Yersinia*: cellular aspects of host-bacteria interactions in enteric diseases. *Gut Pathog.* 2010;2(1):8. doi: 10.1186/1757-4749-2-8.
121. Rendón MA, Saldaña Z, Erdem AL, Monteiro-Neto V, Vázquez A, Kaper JB, *et al.* Commensal and pathogenic *Escherichia coli* use a common pilus adherence factor for epithelial cell colonization. *Proc Natl Acad Sci U S A.* 2007;104(25):10637-10642.

122. Robin F, Delmas J, Brebion A, Dubois D, Constantin JM, Bonnet R. TEM-158 (CMT-9), a new member of the CMT-type extended-spectrum β -lactamases. *Antimicrob Agents Chemother.* 2007;51(11):4181-4183.
123. Rossolini GM, D'Andrea MM, Mugnaioli C. The spread of CTX-M-type extended-spectrum β -lactamases. *Clin Microbiol Infect.* 2008;14 Suppl 1:33-41.
124. Rupp ME¹, Fey PD. Extended spectrum β -lactamase (ESBL)-producing Enterobacteriaceae: considerations for diagnosis, prevention and drug treatment. *Drugs.* 2003;63(4):353-65.
125. Sabaté M, Tarragó R, Navarro F, Miró E, Vergés C, Barbé J, *et al.* Cloning and sequence of the gene encoding a novel cefotaxime-hydrolyzing β -lactamase (CTX-M-9) from *Escherichia coli* in Spain. *Antimicrob Agents Chemother.* 2000;44(7):1970-3.
126. Salverda ML, De Visser JA, Barlow M. Natural evolution of TEM-1 β -lactamase: experimental reconstruction and clinical relevance. *FEMS Microbiol Rev.* 2010;34(6):1015-1036.
127. Salyers AA, Gupta A, Wang Y. Human intestinal bacteria as reservoirs for antibiotic resistance genes. *Trends Microbiol.* 2004;12(9):412-6.
128. Sasirekha B, Shivakumar S. Occurrence of Plasmid-Mediated AmpC β -Lactamases Among *Escherichia coli* and *Klebsiella pneumoniae* Clinical Isolates in a Tertiary Care Hospital in Bangalore. *Indian J Microbiol.* 2012;52(2):174-9.
129. Servin AL. Pathogenesis of Afa/Dr diffusely adhering *Escherichia coli*. *Clin Microbiol Rev.* 2005;18(2):264-92.
130. Shah AA, Hasan F, Ahmed S, Hameed A. Extended-spectrum β -lactamases (ESbLs): characterization, epidemiology and detection. *Crit Rev Microbiol.* 2004;30(1):25-32.

131. Sidjabat HE, Paterson DL, Qureshi ZA, Adams-Haduch JM, O'Keefe A, Pascual A, *et al.* Clinical features and molecular epidemiology of CMY-type β -lactamase-producing *Escherichia coli*. *Clin Infect Dis*. 2009;48(6):739-44.
132. Singtohin S, Chanawong A, Lulitanond A, Sribenjalux P, Auncharoen A, Kaewkes W, *et al.* CMY-2, CMY-8b, and DHA-1 plasmid-mediated AmpC β -lactamases among clinical isolates of *Escherichia coli* and *Klebsiella pneumoniae* from a university hospital, Thailand. *Diagn Microbiol Infect Dis*. 2010;68(3):271-7.
133. Skurnik D, Le Menac'h A, Zurakowski D, Mazel D, Courvalin P, Denamur E, *et al.* Integron-associated antibiotic resistance and phylogenetic grouping of *Escherichia coli* isolates from healthy subjects free of recent antibiotic exposure. *Antimicrob Agents Chemother*. 2005;49(7):3062-5.
134. Song W, Kim JS, Kim HS, Yong D, Jeong SH, Park MJ, *et al.* Increasing trend in the prevalence of plasmid-mediated AmpC β -lactamases in Enterobacteriaceae lacking chromosomal ampC gene at a Korean university hospital from 2002 to 2004. *Diagn Microbiol Infect Dis*. 2006;55(3):219-24.
135. Sougakoff, W., S. Goussard, and P. Courvalin. The TEM-3 β -lactamase, which hydrolyzes broad-spectrum cephalosporins, is derived from the TEM-2 penicillinase by two amino acid substitutions. *FEMS Microbiol Lett*. 1988;56(3):343-348.
136. Stapleton PD, Shannon KP, French GL. Carbapenem resistance in *Escherichia coli* associated with plasmid-determined CMY-4 β -lactamase production and loss of an outer membrane protein. *Antimicrob Agents Chemother*. 1999;43(5):1206-10.
137. Strynadka NC, Adachi H, Jensen SE, Johns K, Sielecki A, Betzel C, Sutoh K, *et al.* Molecular structure of the acyl-enzyme intermediate in β -lactam hydrolysis at 1.7 Å resolution. *Nature*. 1992;359(6397):700-5.

138. Su LH, Chen HL, Chia JH, Liu SY, Chu C, Wu TL, *et al.* Distribution of a transposon-like element carrying bla(CMY-2) among *Salmonella* and other Enterobacteriaceae. *J Antimicrob Chemother.* 2006;57(3):424-9.
139. Sykes, R. B., and K. Bush. 1982. Physiology, biochemistry and inactivation of β -lactamases, p. 155–207. *In* R. B. Morin and M. Gorman (ed.), *The chemistry and biology of β -lactam antibiotics*, vol. 3. Academic Press, London, England.
140. Stapleton PD, Shannon KP, French GL. Carbapenem resistance in *Escherichia coli* associated with plasmid-determined CMY-4 β -lactamase production and loss of an outer membrane protein. *Antimicrob Agents Chemother.* 1999;43(5):1206-10.
141. Tan TY, Ng LS, He J, Koh TH, Hsu LY. Evaluation of screening methods to detect plasmid-mediated AmpC in *Escherichia coli*, *Klebsiella pneumoniae*, and *Proteus mirabilis*. *Antimicrob Agents Chemother.* 2009;53(1):146-9.
142. Tharavichitkul P, Khantawa B, Bousoung V, Boonchoo M. Activity of Fosfomycin Against Extended-Spectrum- β -Lactamase-Producing *Klebsiella pneumoniae* and *Escherichia coli* in Maharaj Nakorn Chiang Mai Hospital. *J Infect Dis Antimicrob Agents.* 2005;22:121-26.
143. Totsika M, Moriel DG, Idris A, Rogers BA, Wurpel DJ, Phan MD, *et al.* Uropathogenic *Escherichia coli* mediated urinary tract infection. *Curr Drug Targets.* 2012;13(11):1386-1399.
144. Tribuddharat C, Srifuengfung S, Chiangjong W. A Correlation between Phenotypes and Genotypes of Extended-Spectrum β -Lactamase (ESBL)-Producing *Klebsiella pneumoniae* in a University Hospital, Thailand. *J Infect Dis Antimicrob Agents* 2007;24:117-23.

145. Tzouveleki LS, Tzelepi E, Tassios PT, Legakis NJ. CTX-M-type β -lactamases: an emerging group of extended-spectrum enzymes. *Int J Antimicrob Agents*. 2000;14(2):137-42.
146. Vogt RL, Dippold L. *Escherichia coli* O157:H7 outbreak associated with consumption of ground beef, June-July 2002. *Public Health Rep*. 2005;120(2):174-8.
147. van Essen-Zandbergen A, Smith H, Veldman K, Mevius D. Occurrence and characteristics of class 1, 2 and 3 integrons in *Escherichia coli*, *Salmonella* and *Campylobacter* spp. in the Netherlands. *J Antimicrob Chemother*. 2007;59(4):746-50.
148. Van Hoek AH, Mevius D, Guerra B, Mullany P, Roberts AP, Aarts HJ. Acquired antibiotic resistance genes: an overview. *Front Microbiol*. 2011;2:203.
149. Wang XR, Chen JC, Kang Y, Jiang N, An SC, Gao ZC. Prevalence and characterization of plasmid-mediated blaESBL with their genetic environment in *Escherichia coli* and *Klebsiella pneumoniae* in patients with pneumonia. *Chin Med J (Engl)*. 2012;125(5):894-900.
150. Wellington EM, Boxall AB, Cross P, Feil EJ, Gaze WH, Hawkey PM, *et al*. The role of the natural environment in the emergence of antibiotic resistance in gram-negative bacteria. *Lancet Infect Dis*. 2013;13(2):155-165.
151. Wicheanno J. Comparison of the method for detection of ESBL and AmpC-producing *Escherichia coli* isolated from patient in Maharaj Nakorn Chiangmai Hospital. Term Paper. Bachelor of Science (Medical Technology), Chiang Mai University, February 2010.
152. Wu SW, Dornbusch K, Kronvall G, Norgren M. Characterization and nucleotide sequence of a *Klebsiella oxytoca* cryptic plasmid encoding a CMY-type β -lactamase: confirmation that the plasmid-mediated cephamycinase originated from the *Citrobacter freundii* AmpC β -lactamase. *Antimicrob Agents Chemother*. 1999;43(6):1350-7.

153. Yan JJ, Ko WC, Wu HM, Tsai SH, Chuang CL, Wu JJ. Complexity of *Klebsiella pneumoniae* isolates resistant to both cephamycins and extended-spectrum cephalosporins at a teaching hospital in Taiwan. *J Clin Microbiol.* 2004;42(11):5337-40.



ลิขสิทธิ์มหาวิทยาลัยเชียงใหม่
Copyright© by Chiang Mai University
All rights reserved